Trials / Withdrawn
WithdrawnNCT05504486
Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
A Phase 4, Multicenter, Single-arm, Open-label, Interventional fMRI Trial to Assess the Effect of Brexpiprazole as Adjunctive Therapy on Functional Brain Network Organization in Adults With Major Depressive Disorder and Symptoms of Anxiety
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to use fMRI to evaluate the effects of brexpiprazole as add-on therapy to antidepressants on brain connectivity in individuals with MDD and symptoms of anxiety, aged 18 to 65.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brexpiprazole | Oral tablet; take once daily; target daily dose of 2 mg |
Timeline
- Start date
- 2022-08-29
- Primary completion
- 2023-03-22
- Completion
- 2023-04-05
- First posted
- 2022-08-17
- Last updated
- 2023-01-30
Source: ClinicalTrials.gov record NCT05504486. Inclusion in this directory is not an endorsement.